Bipartisan Letter Concerned Foreign Inspection of Drug Supply Chain Inadequate
The leadership of the House Energy and Commerce Committee from both parties is asking for more data from the Food and Drug Administration, and is requesting a Government Accountability Office study on inspections of foreign drug manufacturing facilities.
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
Chairman Frank Pallone, Jr., D-N.J.; ranking member Greg Walden, R-Ore.; Health Subcommittee ranking member Michael Burgess, R-Texas; Oversight and Investigations Subcommittee Chair Diana DeGette, D-Colo.; and Oversight and Investigations ranking member Brett Guthrie, R-Ky., signed both letters, sent June 28.
The letters were inspired by recalls of contaminated blood pressure medications manufactured in China and India and press reports on the inspection system overseas. The letter to the FDA acknowledged that the agency has been cooperating with committee staff, but said they are still concerned that the FDA does not have the appropriate authority, resources and management practices to properly oversee foreign manufacturing of prescription drugs.